PL3890833T3 - Synergistyczne kompozycje zawierające (r)-2-(2-oksopirolidyn-1-ylo)butanoamid i (s)-2-(2-oksopirolidyn-1-ylo)butanoamid w stosunku nieracemicznym - Google Patents
Synergistyczne kompozycje zawierające (r)-2-(2-oksopirolidyn-1-ylo)butanoamid i (s)-2-(2-oksopirolidyn-1-ylo)butanoamid w stosunku nieracemicznymInfo
- Publication number
- PL3890833T3 PL3890833T3 PL19813837.2T PL19813837T PL3890833T3 PL 3890833 T3 PL3890833 T3 PL 3890833T3 PL 19813837 T PL19813837 T PL 19813837T PL 3890833 T3 PL3890833 T3 PL 3890833T3
- Authority
- PL
- Poland
- Prior art keywords
- oxopyrrolidin
- butanamide
- synergistic compositions
- racemic ratio
- racemic
- Prior art date
Links
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 title 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18210106 | 2018-12-04 | ||
| PCT/EP2019/083594 WO2020115093A1 (en) | 2018-12-04 | 2019-12-04 | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3890833T3 true PL3890833T3 (pl) | 2023-09-18 |
Family
ID=64604549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19813837.2T PL3890833T3 (pl) | 2018-12-04 | 2019-12-04 | Synergistyczne kompozycje zawierające (r)-2-(2-oksopirolidyn-1-ylo)butanoamid i (s)-2-(2-oksopirolidyn-1-ylo)butanoamid w stosunku nieracemicznym |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220047548A1 (pl) |
| EP (1) | EP3890833B1 (pl) |
| JP (2) | JP2022510363A (pl) |
| KR (1) | KR20210099567A (pl) |
| CN (1) | CN113164767A (pl) |
| AU (1) | AU2019391309A1 (pl) |
| BR (1) | BR112021010739A2 (pl) |
| CA (1) | CA3117350A1 (pl) |
| CO (1) | CO2021007055A2 (pl) |
| EA (1) | EA202191485A1 (pl) |
| EC (1) | ECSP21040300A (pl) |
| ES (1) | ES2953785T3 (pl) |
| HU (1) | HUE062575T2 (pl) |
| IL (1) | IL283441A (pl) |
| JO (1) | JOP20210082A1 (pl) |
| MX (1) | MX2021006243A (pl) |
| PH (1) | PH12021551305A1 (pl) |
| PL (1) | PL3890833T3 (pl) |
| SG (1) | SG11202105863PA (pl) |
| WO (1) | WO2020115093A1 (pl) |
| ZA (1) | ZA202102701B (pl) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412358D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| CA2488325C (en) * | 2004-11-22 | 2010-08-24 | Apotex Pharmachem Inc. | Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| CN101511786A (zh) * | 2006-07-25 | 2009-08-19 | Zach系统股份公司 | 制备左乙拉西坦的方法 |
| WO2009058261A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| EP2098526B1 (en) | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| EP2671858A1 (en) * | 2012-06-08 | 2013-12-11 | Université Catholique De Louvain | Process for chiral resolution of etiracetam |
| JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
-
2019
- 2019-12-04 JP JP2021531433A patent/JP2022510363A/ja active Pending
- 2019-12-04 EA EA202191485A patent/EA202191485A1/ru unknown
- 2019-12-04 PH PH1/2021/551305A patent/PH12021551305A1/en unknown
- 2019-12-04 CA CA3117350A patent/CA3117350A1/en active Pending
- 2019-12-04 US US17/299,928 patent/US20220047548A1/en not_active Abandoned
- 2019-12-04 HU HUE19813837A patent/HUE062575T2/hu unknown
- 2019-12-04 WO PCT/EP2019/083594 patent/WO2020115093A1/en not_active Ceased
- 2019-12-04 MX MX2021006243A patent/MX2021006243A/es unknown
- 2019-12-04 KR KR1020217016689A patent/KR20210099567A/ko not_active Ceased
- 2019-12-04 BR BR112021010739-8A patent/BR112021010739A2/pt unknown
- 2019-12-04 CN CN201980076384.6A patent/CN113164767A/zh active Pending
- 2019-12-04 JO JOP/2021/0082A patent/JOP20210082A1/ar unknown
- 2019-12-04 AU AU2019391309A patent/AU2019391309A1/en not_active Abandoned
- 2019-12-04 SG SG11202105863PA patent/SG11202105863PA/en unknown
- 2019-12-04 PL PL19813837.2T patent/PL3890833T3/pl unknown
- 2019-12-04 ES ES19813837T patent/ES2953785T3/es active Active
- 2019-12-04 EP EP19813837.2A patent/EP3890833B1/en active Active
-
2021
- 2021-04-22 ZA ZA2021/02701A patent/ZA202102701B/en unknown
- 2021-05-25 IL IL283441A patent/IL283441A/en unknown
- 2021-05-28 CO CONC2021/0007055A patent/CO2021007055A2/es unknown
- 2021-06-03 EC ECSENADI202140300A patent/ECSP21040300A/es unknown
-
2024
- 2024-10-11 JP JP2024178838A patent/JP2025020146A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA202191485A1 (ru) | 2021-08-30 |
| AU2019391309A1 (en) | 2021-05-20 |
| PH12021551305A1 (en) | 2022-05-16 |
| HUE062575T2 (hu) | 2023-11-28 |
| SG11202105863PA (en) | 2021-07-29 |
| JP2025020146A (ja) | 2025-02-12 |
| EP3890833B1 (en) | 2023-06-07 |
| ZA202102701B (en) | 2023-10-25 |
| JP2022510363A (ja) | 2022-01-26 |
| CN113164767A (zh) | 2021-07-23 |
| US20220047548A1 (en) | 2022-02-17 |
| CO2021007055A2 (es) | 2021-06-10 |
| MX2021006243A (es) | 2021-08-11 |
| ES2953785T3 (es) | 2023-11-16 |
| WO2020115093A1 (en) | 2020-06-11 |
| CA3117350A1 (en) | 2020-06-11 |
| KR20210099567A (ko) | 2021-08-12 |
| EP3890833A1 (en) | 2021-10-13 |
| BR112021010739A2 (pt) | 2021-08-24 |
| EP3890833C0 (en) | 2023-06-07 |
| JOP20210082A1 (ar) | 2023-01-30 |
| ECSP21040300A (es) | 2021-07-30 |
| IL283441A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201912243PA (en) | Methods and compositions for treating a bleeding event in a subject having hemophilia | |
| ZA202207279B (en) | Composition rich in polyphenols and flavonoids for use as a biostimulant and antimicrobial for use in agriculture | |
| IL271758A (en) | Statin preparations and methods for use in the treatment of synuclein pathologies | |
| PL3908252T3 (pl) | Peptydy i kompozycje do stosowania w kosmetyce | |
| IL317571A (en) | Preparations and use of TIRZEPATIDE | |
| IL270833B (en) | Synergistic preparations containing (r)-dimiracetam (1) and (s)-dimidacetam (2) in a non-sequential ratio | |
| GB2599803B (en) | Methods and compositions for promoting health in a subject | |
| ZA202103276B (en) | Bioflavonoid compositions and their use | |
| ZA202100525B (en) | Synergistically effective herbicide composition comprising pyridate and at least one defined 4-hppd inhibitor | |
| IL283441A (en) | Synergistic preparations containing (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-serial ratio | |
| PL3946260T3 (pl) | Postacie użytkowe pregabaliny i ich zastosowanie | |
| PL4168523T3 (pl) | Kompozycje i ich zastosowanie | |
| IL299029A (en) | Ready-made 3D printed vehicles and their uses | |
| PL3930727T3 (pl) | Kompozycja przeciwutleniająca zawierająca polidatynę i acetylocysteinę | |
| GB201901413D0 (en) | Compositions and their use | |
| ZA202104787B (en) | Preservative systems and compositions comprising them | |
| GB202107254D0 (en) | Compositions and use thereof | |
| GB202014427D0 (en) | Composition and use | |
| GB201913816D0 (en) | Novel compositions having use in therapy | |
| GB201907591D0 (en) | Composition and use | |
| GB201906765D0 (en) | Improvement in and relating | |
| GB2571766B (en) | Dental composition and dental paste comprising same | |
| GB202000879D0 (en) | Synergistic compositions | |
| AU2019902828A0 (en) | Compositions and methods for promoting health in a subject | |
| GB201907351D0 (en) | Compositions and uses thereof |